CMND PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

CMND ▲ +22.39% at T+5d

NEUTRAL call ✓ call won +22.39% · α vs SPY +21.31% · entry $2.59 → $3.17

Next anchor: T+20d in 3d

Last close $3.07 (close Jun 18) · +18.53% from $2.59 entry

Entry anchored
May 22, 03:59 PM ET
via Databento tick

T+1d

-4.25%

call -4.25% · α -4.26%

$2.48

settled 25d ago

T+5d

+22.39%

call +22.39% · α +21.31%

$3.17

settled 19d ago

T+20d

—

call — · α —

—

in 3d

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Clearmind Medicine announced that the Johns Hopkins Medicine IRB has approved its Phase I/II trial of CMND-100 for Alcohol Use Disorder, allowing the company to proceed with Parts B and C. This is a routine clinical milestone for a micro-cap biotech with no financial data or revenue, and the stock has historically declined on similar neutral news.

Actionable Insight

This is a routine clinical milestone with no hard financial data. The stock has historically declined on similar neutral news (avg T+20 -13.33%). Monitor for actual patient enrollment data or financing updates, but no immediate catalyst for upside.

Key Facts

Johns Hopkins Medicine IRB approved Phase I/II trial of CMND-100 for Alcohol Use Disorder
Approval permits Clearmind to proceed with Parts B and C of the multicenter study
No financial terms, revenue, or guidance disclosed in the press release
Clearmind is a clinical-stage biotech with no approved products or revenue

Financial Impact

No financial figures disclosed; pre-revenue clinical-stage company

Risk Factors

No revenue or near-term commercialization path; cash burn risk
Clinical trial failure or delay could be catastrophic for a single-asset micro-cap
Historical pattern of negative stock reaction to neutral news

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3301074

36 reports for CMND

T+1T+5T+20T+60

50% Hit rate 6 of 12 directional calls best @ T+20▲ +71.18%Apr 20, 2026

Filters

Reports for CMND — sortable, filterable
	Type				Now
Jun 18, 2026 2d ago	6-K NEUTRAL ★ 4/10	$3.07 awaiting T+1	awaiting T+1	—	$3.07 (−0.00%)
Jun 18, 2026 2d ago	Press Release NEUTRAL ★ 3/10	$3.05 awaiting T+1	awaiting T+1	—	$3.07 (+0.66%)
Jun 16, 2026 4d ago	6-K NEUTRAL ★ 4/10	$3.14 $3.14	· 0.00%	▲ +1.25%	$3.07 (−2.23%)
Jun 12, 2026 8d ago	3 NEUTRAL ★ 2/10	$3.37 $3.14	▼ −6.82%	▼ −6.23%	$3.07 (−8.90%)
Jun 5, 2026 15d ago	Press Release NEUTRAL ★ 2/10	$3.98 $3.79	▼ −4.77%	▼ −5.00%	$3.07 (−22.86%)
May 29, 2026 22d ago	6-K NEUTRAL ★ 3/10	$3.58 $3.17	▼ −11.45%	▼ −11.73%	$3.07 (−14.25%)
May 29, 2026 22d ago	Press Release NEUTRAL ★ 3/10	$3.58 $3.17	▼ −11.45%	▼ −11.73%	$3.07 (−14.25%)
May 26, 2026 25d ago	6-K NEUTRAL ★ 4/10	$2.59 $2.48	▼ −4.25%	▼ −4.26%	$3.07 (+18.53%)
May 26, 2026 25d ago	Press Release NEUTRAL ★ 4/10	$2.59 $2.48	▼ −4.25%	▼ −4.26%	$3.07 (+18.53%)
May 19, 2026 4w ago	6-K BEARISH ★ 6/10	$2.36 $2.52	▼ −6.78%	▼ −5.74%	$3.07 (−30.08%)

US Market Status

Market Closed — Opens Mon (29h 33m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access